JSL
TEVA icon

JT Stratford LLC’s Teva Pharmaceuticals TEVA Stock Holding History

JT Stratford LLC’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-15,003
Closed -$146K – 225
2021
Q3 		$146K Sell
15,003
-66
-0.4% -$618 0.04% 208
2021
Q2 		$149K Sell
15,069
-181
-1% -$1.92K 0.05% 204
2021
Q1 		$176K Sell
15,250
-1,050
-6% -$12K 0.06% 194
2020
Q4 		$157K Buy
+16,300
New +$156K 0.06% 175

Other funds holding TEVA

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

JT Stratford LLC's TEVA Position: Q4 2021 in Review

JT Stratford LLC sold out of Teva Pharmaceuticals (TEVA) in Q4 2021, closing a stake of 15,003 shares — an estimated $146K sold.

JT Stratford LLC first reported a position in TEVA in Q4 2020 and held it in 4 quarters. The position peaked at $176K in Q1 2021. 450 funds tracked by Wall St. Rank hold TEVA as of Q4 2021.

  • JT Stratford LLC reported no remaining Teva Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
  • JT Stratford LLC sold 15,003 Teva Pharmaceuticals shares in Q4 2021, an estimated $146K.
  • JT Stratford LLC first reported a position in Teva Pharmaceuticals in Q4 2020 and held it in 4 quarters.
  • JT Stratford LLC's Teva Pharmaceuticals position peaked at $176K in Q1 2021.
  • 450 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q4 2021.

Based on JT Stratford LLC's 13F filing for Q4 2021, filed 11 Feb 2022.